Campuses: FH.com Home button

Clinical Trials Currently Open

Below is the list of clinical trials currently available at the Cancer Institute of Florida Hospital Memorial Medical Center.
For any questions or to learn if you qualify for a trial, please contact our clinical trial research coordinator at (386) 231-4023.

 

Breast Cancer Studies

#311-06-EP Breast Cancer Collaborative Registry Trial (BCCR): A Breast Cancer Information Registry for Participants with Breast Cancer or Characteristics of Hereditary Breast Cancer.

https://clinicaltrials.gov/ct2/show/NCT00666731
 

Lung Cancer Studies

LUN 298/ GO29437:  A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy And Safety of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin +Paclitaxel or MPDL3280A In Combination with Carboplatin + Nab-Paclitaxel Versus Carboplatin + Paclitaxel in Chemotherapy-Naïve Patients with Stage IV Squamous Non-Small Cell Lung Cancer (NCT02367794)

https://clinicaltrials.gov/ct2/show/NCT02367794

LUN 299/GO29537:  A Phase III, Multicenter, Randomized, Open-Label Study Evaluating The Efficacy And Safety Of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Nab-Paclitaxel For Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NCT02367781)

https://clinicaltrials.gov/ct2/show/NCT02367781

LUN 308/ GO29527:  A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3280A (Atezolizumab, Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Chemotherapy in Patients With Lung Cancer (NCT02486718)

https://clinicaltrials.gov/ct2/show/NCT02486718  (coming soon)

Melanoma Studies

Amgen 20110266: A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of  Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB  to IVM1a Melanoma

https://clinicaltrials.gov/ct2/show/NCT02211131?term=Amgen+20110266&rank=1
 

Amgen 20120139:    "A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with Melanoma Who Previously Received Talimogene Laherparepvec."  (coming soon)

https://clinicaltrials.gov/ct2/show/NCT02173171
 

Glioblastoma Studies

A221101 “A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodfinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma." 

https://clinicaltrials.gov/ct2/show/study/NCT01781468?show_locs=Y#locn